PHILADELPHIA and NEW YORK, April 17,
2018 /PRNewswire/ -- Tikun Olam, the world
leader in cannabis science, and Ilera Healthcare,
Pennsylvania's premier medical
marijuana cultivator, processor and dispenser, have finalized a
deal to bring Tikun's world-renowned medical marijuana strains to
medical cannabis patients in the Keystone State later this
year.
This partnership combines Tikun Olam's history of peer-reviewed
scientific research and unprecedented clinical data collection with
Ilera's expertise in formulating and delivering high-quality
pharmaceutical-grade medical cannabis products to Pennsylvanians.
Products developed from Tikun Olam's proprietary strains, including
its world-renowned Avidekel™ high-CBD strain, will be available in
vape oils, tinctures and topical formulations.
Tikun Olam has created numerous cannabis strains designed to
deliver symptomatic relief for specific conditions in line with the
17 medical conditions approved for medical cannabis use in
Pennsylvania, including autism,
cancer, PTSD, epilepsy, Crohn's Disease/Colitis, chronic pain and
neuropathy, to name a few.
"Tikun Olam has spent years developing our strains through
scientific methods," says Tikun CEO Bernie
Sucher. "Finding the ideal partner that shares our focus on
quality control and consistency from seed to sale was a top
priority for our Pennsylvania
launch, and Ilera Healthcare was our top choice."
Greg Rochlin, CEO of Ilera
Healthcare, sees this as a natural partnership. "Ilera is dedicated
to producing consistent, high-quality medications with effects that
are supported by data, and so is Tikun Olam."
About Tikun Olam
Tikun Olam ("repair the world" in
Hebrew) is the world's leading cannabis brand and globally
recognized as the pioneer of modern medical cannabis. Operating as
a commercial venture for over 10 years, Tikun Olam's products have
been used since 2010 in ongoing clinical trials in Israel's regulated medical cannabis market,
treating over 20,000 patients for a variety of symptoms of medical
conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn's
Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain
and neuropathy. Through this access to patients, medical personnel
and data collection, Tikun Olam has developed multiple proprietary
strains, including the first-ever, high-CBD, "high-less" strain
Avidekel™, its popular high-THC strain Alaska™, and its
"one-to-one" CBD/THC strain Midnight™. Tikun Olam's U.S.
operations, established in 2015 as T.O. Global LLC, is a joint
venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar
partnerships in Canada (TSX: LEAF)
and Australia, all in support of
its global mission to educate the traditional medical community and
its patients on the applications of cannabis as a scientifically
proven wellness product. Visit www.tikunolamusa.com, and follow us
on Facebook, Twitter, and Instagram.
About Ilera Healthcare
Ilera Healthcare is
Pennsylvania's premier medical
marijuana cultivator, processor and dispenser, offering patients
registered in the Pennsylvania Medical Marijuana program with
products that provide the relief they want to lead healthier lives.
Ilera Healthcare operates its primary dispensary in Plymouth Meeting, Pennsylvania, with plans to
open two additional dispensary sites in Pennsylvania within the year. Through their
state-of-the-art cultivation, extraction, and processing facility
in Waterfall, Pennsylvania, Ilera
Healthcare strives to drive medical advancements through its
formulations and shape the future of medical marijuana-based
therapies. For more information about Ilera Healthcare, visit
http://www.ilerahealthcare.com.
CONTACTS:
T.O. Global LLC/ Tikun™
Chief Marketing Officer
Stephen Gardner
sgardner@tikunolam.com
Media Relations
Type A Media
Tracey Henry / Brenda
Loughery
Tracey@type-a-media.com
Brenda@type-a-media.com
Ilera Healthcare
Altay
Akgun
aakgun@ilerahealthcare.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/global-cannabis-pioneer-tikun-olam-and-ilera-healthcare-announce-pennsylvania-partnership-to-deliver-science-backed-cannabis-products-to-pa-mmj-patients-300630781.html
SOURCE Tikun Olam